Investigational drug · Phase 3
HR070803
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "HR070803"
First trial start
2023
Aug 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HR070803", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HR070803" as an intervention, largest first.
- HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic CancerPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05751850 · 778 participants (planned) · Start Jun 13, 2023 · Primary completion Dec 30, 2024
Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate; nab-paclitaxel; gemcitabine · For: First-line Treatment of Advanced Pancreatic Cancer
Sites: Beijing, China
- A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal CancerPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05945901 · 669 participants · Start Aug 14, 2023 · Primary completion Dec 1, 2025
Drug: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab; HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab · For: Colorectal Cancer
Sites: Guangzhou, China
- HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06217042 · 524 participants (planned) · Start Feb 5, 2024 · Primary completion Mar 30, 2027
Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate; gemcitabine; capecitabine · For: Pancreatic Cancer
Sites: Shanghai, China
- HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic CancerPivotal-lookingNot yet recruiting
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06383078 · 120 participants (planned) · Start Apr 20, 2024 · Primary completion Mar 1, 2027
Drug: HR070803; Oxaliplatin and 3 more · For: Efficacy and Safety
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05425472 · 30 participants (planned) · Start Jul 27, 2022 · Primary completion Jan 30, 2023
Drug: HR070803 · For: Advanced Esophageal Cancer
Sites: Shanghai, China
Sun Yat-sen UniversityAcademic, hospital or other
NCT06827717 · 29 participants (planned) · Start Apr 15, 2025 · Primary completion Apr 2027
Drug: irinotecan liposome (II) + temozolomide + fluzoparib · For: Ewing Sarcoma
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China.
Huang J, Ye H, Lin J, et al. · PLoS One 2026
- Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.
Xu Q, Zhao X, Wang X, et al. · BMC Med 2025
- Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
Cui J, Qin S, Zhou Y, et al. · Signal Transduct Target Ther 2024
- Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.
Ji D, Shen W, Li T, et al. · Invest New Drugs 2024
- China special issue on gastrointestinal tumors-Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study.
Quan M, Chen J, Chen Z, et al. · Int J Cancer 2023
Also in development for Colorectal Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.